Published in Proc Natl Acad Sci U S A on April 25, 2005
Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A (2007) 2.13
Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. J Virol (2009) 1.63
Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol (2006) 1.54
Review: The neurobiology of varicella zoster virus infection. Neuropathol Appl Neurobiol (2011) 1.45
The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol (2009) 1.38
Varicella-zoster virus infection of differentiated human neural stem cells. J Virol (2011) 1.34
Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. J Virol (2007) 1.29
Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol (2008) 1.23
Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol (2014) 1.22
Productive varicella-zoster virus infection of cultured intact human ganglia. J Virol (2007) 1.22
Varicella zoster virus infection of highly pure terminally differentiated human neurons. J Neurovirol (2012) 1.20
Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A (2011) 1.16
Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog (2011) 1.14
Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol (2010) 1.14
Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog (2011) 1.10
Expression of varicella-zoster virus immediate-early regulatory protein IE63 in neurons of latently infected human sensory ganglia. J Virol (2010) 1.08
Simian varicella virus pathogenesis. Curr Top Microbiol Immunol (2010) 1.08
Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I. Proc Natl Acad Sci U S A (2007) 1.07
Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev (2013) 1.06
Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS One (2012) 1.05
Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cells. J Virol (2011) 1.01
Characterization of the host immune response in human Ganglia after herpes zoster. J Virol (2010) 1.00
Varicella-zoster virus reactivation from multiple ganglia: a case report. J Med Case Rep (2009) 0.98
Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication. J Virol (2007) 0.95
Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts. J Virol Methods (2008) 0.95
Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci U S A (2009) 0.94
Varicella zoster virus (VZV)-human neuron interaction. Viruses (2013) 0.93
A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation. J Gen Virol (2015) 0.93
T-Cell tropism of simian varicella virus during primary infection. PLoS Pathog (2013) 0.92
Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis. J Virol (2010) 0.92
Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model. J Virol (2010) 0.92
Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region. J Virol (2006) 0.91
VZV infection of keratinocytes: production of cell-free infectious virions in vivo. Curr Top Microbiol Immunol (2010) 0.85
Dissection of a novel nuclear localization signal in open reading frame 29 of varicella-zoster virus. J Virol (2005) 0.85
ORF7 of varicella-zoster virus is a neurotropic factor. J Virol (2012) 0.85
Herpes simplex virus 1 tropism for human sensory ganglion neurons in the severe combined immunodeficiency mouse model of neuropathogenesis. J Virol (2012) 0.84
Clinical and molecular aspects of varicella zoster virus infection. Future Neurol (2009) 0.84
Three-dimensional normal human neural progenitor tissue-like assemblies: a model of persistent varicella-zoster virus infection. PLoS Pathog (2013) 0.83
Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells. J Virol (2011) 0.82
Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge. J Virol (2014) 0.78
Animal models of varicella zoster virus infection. Pathogens (2013) 0.78
Dysregulated Glycoprotein B Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription During Infection. J Virol (2016) 0.77
Enforced expression of microRNA-21 influences the replication of varicella-zoster virus by triggering signal transducer and activator of transcription 3. Exp Ther Med (2014) 0.77
Pathogenesis of varicelloviruses in primates. J Pathol (2015) 0.76
Characterization of the immune response in ganglia after primary simian varicella virus infection. J Neurovirol (2015) 0.76
Acute Simian Varicella Virus Infection Causes Robust and Sustained Changes in Gene Expression in the Sensory Ganglia. J Virol (2016) 0.75
Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo. J Virol (2016) 0.75
Primary varicella in an immunocompetent adult. J Clin Aesthet Dermatol (2009) 0.75
Neuronal Subtype and Satellite Cell Tropism Are Determinants of Varicella-Zoster Virus Virulence in Human Dorsal Root Ganglia Xenografts In Vivo. PLoS Pathog (2015) 0.75
In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency. Proc Natl Acad Sci U S A (2016) 0.75
Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A (1991) 16.94
Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med (2000) 6.43
Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A (1988) 3.49
Herpesviruses use bidirectional fast-axonal transport to spread in sensory neurons. Proc Natl Acad Sci U S A (2001) 3.34
Live vaccine used to prevent the spread of varicella in children in hospital. Lancet (1974) 3.24
Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci U S A (1996) 2.71
Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. J Virol (2000) 2.70
Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A (1998) 2.65
The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med (1991) 2.62
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol (1996) 2.41
Varicella-zoster virus DNA in human sensory ganglia. Nature (1984) 2.34
Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol (1999) 2.25
Varicella-zoster virus gene expression in latently infected and explanted human ganglia. J Virol (2000) 2.23
Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med (2004) 1.85
Varicella-zoster virus gene 66 transcription and translation in latently infected human Ganglia. J Virol (2003) 1.80
Characterization of regulatory functions of the varicella-zoster virus gene 63-encoded protein. J Virol (1992) 1.68
Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A (1995) 1.68
Physical and functional interaction between the varicella zoster virus IE63 and IE62 proteins. Virology (2002) 1.47
Varicella-Zoster virus gene expression in latently infected rat dorsal root ganglia. Virology (2001) 1.45
Quantitation of latent varicella-zoster virus DNA in human trigeminal ganglia by polymerase chain reaction. J Virol (1993) 1.41
Interactions among structural proteins of varicella zoster virus. Arch Virol Suppl (2001) 1.27
Prevalence of varicella-zoster virus DNA in dissociated human trigeminal ganglion neurons and nonneuronal cells. J Virol (1999) 1.25
An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J Neurosci Res (1990) 1.25
Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences. J Virol (2004) 1.24
Phosphorylation of varicella-zoster virus IE63 protein by casein kinases influences its cellular localization and gene regulation activity. J Biol Chem (2002) 1.23
The varicella-zoster virus open reading frame 63 latency-associated protein is critical for establishment of latency. J Virol (2004) 1.22
Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency. J Virol (2002) 1.17
Varicella-zoster virus gene 63: transcript mapping and regulatory activity. Virology (1995) 1.16
Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J Virol (2004) 1.16
Phosphorylation and nuclear localization of the varicella-zoster virus gene 63 protein. J Virol (1996) 1.14
Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology (2005) 1.09
Varicella-zoster virus infection of human neural cells in vivo. Proc Natl Acad Sci U S A (2004) 1.06
Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol (2003) 1.05
Varicella-zoster virus infection of a human CD4-positive T-cell line. Virology (2000) 1.04
Varicella vaccine: genesis, efficacy, and attenuation. Virology (2001) 0.97
Varicella-zoster virus proteins in skin lesions: implications for a novel role of ORF29p in chickenpox. J Virol (2000) 0.88
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med (2009) 4.71
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood (2010) 3.41
Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol (2006) 2.97
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A (2006) 2.94
Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83
Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med (2002) 2.73
Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol (2006) 2.67
Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis (2008) 2.37
Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. J Immunol (2010) 2.36
Gene expression patterns in human placenta. Proc Natl Acad Sci U S A (2006) 2.33
Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med (2015) 2.04
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A (2009) 2.02
Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med (2004) 1.85
A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol (2007) 1.76
Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis (2009) 1.65
Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation in lipopolysaccharide-induced acute lung injury. Crit Care Med (2012) 1.60
The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood (2011) 1.57
T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest (2004) 1.56
Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother (2013) 1.54
Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol (2006) 1.54
Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol (2002) 1.53
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol (2004) 1.48
High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A (2011) 1.48
Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol (2005) 1.48
Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol (2006) 1.46
Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn (2007) 1.44
The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol (2009) 1.38
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology (2002) 1.37
Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis (2010) 1.36
Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol (2003) 1.33
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood (2012) 1.31
Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol (2002) 1.29
Varicella in the fetus and newborn. Semin Fetal Neonatal Med (2008) 1.29
Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J (2007) 1.28
Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. J Virol (2003) 1.25
Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol (2008) 1.23
Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis (2004) 1.20
Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine (2003) 1.20
Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. J Infect Dis (2003) 1.19
A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis (2006) 1.19
T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol (2005) 1.19
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood (2009) 1.19
Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J Virol (2004) 1.17
Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A (2011) 1.16
Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J Virol (2004) 1.16
Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. J Virol (2008) 1.15
Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog (2011) 1.14
Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol (2010) 1.14
A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res (2005) 1.14
Functions of Varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection. J Virol (2008) 1.13
Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis (2008) 1.12
Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J Virol (2006) 1.12
Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One (2008) 1.11
Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog (2011) 1.10
Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol (2006) 1.10
Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology (2005) 1.09
Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee On Research Related To Measles and Rubella Vaccines and Vaccination, June 2004. J Infect Dis (2005) 1.08
Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I. Proc Natl Acad Sci U S A (2007) 1.07
Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis (2004) 1.06
Varicella-zoster virus infection of human neural cells in vivo. Proc Natl Acad Sci U S A (2004) 1.06
Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol (2007) 1.04
Requirement of varicella-zoster virus immediate-early 4 protein for viral replication. J Virol (2003) 1.03
Varicella-zoster virus open reading frame 10 is a virulence determinant in skin cells but not in T cells in vivo. J Virol (2006) 1.03
Presentation of extranodal natural killer T-cell lymphoma, nasal type, with poorly circumscribed erythematous patches. J Clin Oncol (2009) 1.03
Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism. Proc Natl Acad Sci U S A (2011) 1.03
Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis (2008) 1.02
Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis (2003) 1.01
Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis. J Virol (2009) 1.01
Endonuclease G: a role for the enzyme in recombination and cellular proliferation. Proc Natl Acad Sci U S A (2006) 1.01
Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine (2006) 1.00
TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol (2012) 1.00
Varicella-zoster virus infection triggers formation of an interleukin-1β (IL-1β)-processing inflammasome complex. J Biol Chem (2011) 0.99
Lack of human herpesvirus 8 and Epstein-Barr virus in Kikuchi's histiocytic necrotizing lymphadenitis. Hum Pathol (2003) 0.99
Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol (2013) 0.97
ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo. J Virol (2006) 0.97
Testing for maternal cell contamination in prenatal samples: a comprehensive survey of current diagnostic practices in 35 molecular diagnostic laboratories. J Mol Diagn (2007) 0.96
New viral vaccines. Virology (2006) 0.96
3D reconstruction of VZV infected cell nuclei and PML nuclear cages by serial section array scanning electron microscopy and electron tomography. PLoS Pathog (2012) 0.96
Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication. J Virol (2007) 0.95